Here, we show that fulvestrant has potent therapeutic effects in ERα-/ERβ+ breast cancer and that tamoxifen and fulvestrant in combination enhance tumor regression of ERα+/ERβ+ breast cancer by up-regulation of ERβ. This evidence concerns the gene ESR1 and breast cancer.